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preventable worldwide. More than one million cases are reported annually, with average fatality rates
ranging from 10% to 40% depending on clinical presentation and geographic location. Survivors may suffer
debilitating sequelae that reduce the quality of life for the patient and family members responsible for their
care. Major ﬁnancial burdens are associated with acute treatment and follow-up care, and outbreak man-
agement often places extensive ﬁnancial strains on public health resources. Although the clinical and ﬁnancial
aspects of meningococcal disease burden are straightforward to quantify, other burdens such as lifelong
cognitive deﬁcits, psychological stress, adaptive measures for reintegration into society, familial impact, and
legal costs are systematically overlooked. These and other facets of disease burden are therefore not system-
atically considered in cost-effectiveness analyses that public health authorities take into consideration when
making decisions regarding vaccination programs. Changing the approach for measuring meningococcal dis-
ease burden is necessary to accurately understand the societal consequences of this devastating illness. In this
article, the conventional and under-recognized burdens ofmeningococcal disease are presented anddiscussed.
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http://dx.doi.org/10.1016/j.jadohealth.2016.03.041Invasive meningococcal disease (IMD) is caused by the gram-
negative commensal bacterium Neisseria meningitidis, whose
only known reservoir is the human nasopharyngeal tract [1].
With more than 1.2 million cases reported worldwide each year,
IMD represents a signiﬁcant global public health concern [2].Meningococcal disease is potentially fatal within 24 hours of
onset of illness and has an average case fatality ratio (CFR)
ranging from approximately 10%e20%, which can reach as high
as 40% in patients with septicemia [3e7]. Among survivors, up to
20% may experience permanent or long-term sequelae [8].
The highest rates of IMD are reported in infants younger than
1 year, adolescents, and young adults [1,9]. Geographic region
and season are known to inﬂuence IMD incidence, which ranges
from <1 case to more than 1,000 cases per 100,000 population
[1,5,10,11]. Worldwide, most meningococcal disease is caused by
six serogroups, deﬁned based on differential expression of bac-
terial capsular polysaccharides: A, B, C, W, X, and Y [12,13].
Serogroups A and C are frequently associated with hyperendemic
disease, whereas serogroup B is often the cause of sporadic dis-
ease and outbreaks in developed countries [1,5,14].
Meningococcal disease is dynamic and highly unpredictable,
manifesting as isolated cases or outbreaks. Outbreak cases may
occur in closely grouped temporal clusters ormay be spread across
several years. For example, during a serogroup B outbreak in the
Table 1
Clinical presentation of invasive meningococcal disease and case fatality ratios
Clinical presentation/syndrome Proportion of
IMD diagnoses
Case fatality ratio
Meningococcal disease 10%e40% [5]
Meningococcemia 17%e37% [24,25] 13.2%e40% [5,26]
Meningitis 50% [11] 2%e9% [24,26]
Meningococcemia þ meningitis 4%e22% [24,25] 14%e16.5% [24,26]
Pneumonia 5%e15% [17]
Chronic meningococcemia Rarea [17]
Conjunctivitis/endophthalmitis Rarea [17]
Epiglottitis Rarea [17]
Pericarditis/myocarditis Rarea [17]
Peritonitis Rarea [27]
Septic arthritis/osteomyelitis Rarea [17]
IMD ¼ invasive meningococcal disease.
a Rare diagnoses, <5% of cases.
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ﬁfth case identiﬁed retrospectively [15], whereas cases associated
with a separate outbreak were spread across 2 years [16]. Long
intervals between cases and erratic transmission patterns make
meningococcal disease exceptionally difﬁcult to predict.
This review article presents the global clinical and economic
burden of IMD, highlighting other unconventional aspects of
disease burden that are frequently overlooked.
Clinical Burden of Disease
Clinical presentation
N meningitidis commonly colonizes the nasopharyngeal tract,
but a transition between asymptomatic carriage and invasive
disease can occur within 2 weeks of acquisition [1]. After
attachment to epithelial cells of the upper respiratory tract,
bacteria may spread to the bloodstream or other epithelial sur-
faces, leading to systemic disease [1,17]. The underlying mecha-
nisms of this shift are not fully understood.
Certain groups are at increased risk for IMD because of
physiological, genetic, or environmental characteristics [9,18]. By
age group, infants and adolescents/young adults are at highest
risk [9]. In some countries, increased risk for IMD in adolescents
and young adults may be attributed to increased social mixing
behavior, including bar attendance, smoking, or more than one
kissing partner [19]. Host genetic factors, mainly polymorphisms
in the complement factor H gene, may have roles in susceptibility
to IMD [20]. Polymorphisms in the plasminogen activator in-
hibitor 1 gene, genes encoding Fc receptors of immunoglobulins,
and Toll-like receptors are also thought to correlate with disease
susceptibility and severity [18]. Functional or anatomic asplenia,
complement deﬁciencies, and chronic underlying illnesses such
as membranous glomerulonephritis and immunodeﬁciency are
also considered risk factors for IMD [9,21]. Environmental factors
contributing to increased risk include conﬁned living conditions
such as military barracks and university dormitories, which are
associated with higher nasopharyngeal carriage rates [19]. Travel
to countries or regions with hyperendemic meningococcal dis-
ease and routine handling of N meningitidis in a laboratory are
also risk factors [9,22]. Importantly, most IMD cases occur in
otherwise healthy individuals without identiﬁable risk factors in
nonepidemic circumstances [18,23].
Meningococcal disease onset is characteristically sudden and
may progress to severe disease in as little as 15e24 hours [3].
Symptoms are variable and often difﬁcult to distinguish from
other illnesses, at least during the early stages. Patients may
present with fever, sudden headache, neck stiffness, rash, nausea
and/or vomiting, sensitivity to light, and altered mental status.
Meningococcal disease among infants may have less speciﬁc
symptoms, but a bulging fontanelle may be observed. The
number of patients presenting with speciﬁc clinical features may
also differ between industrialized and developing countries and
between outbreaks [1]. Diagnoses are generally made by con-
ﬁrming the presence of N meningitidis in a normally sterile site
such as blood or cerebrospinal ﬂuid via detection of meningo-
coccal antigens in seroagglutination assays or by PCR for
meningococcal genes [17].
IMDmaymanifest in multiple clinical presentations (Table 1),
with the most common clinical diagnoses being meningitis and
meningococcemia; these may sometimes present together. Pre-
sentation may also differ depending on the infecting Nmeningitidis serogroup. For example, among 879 cases of IMD in
the Netherlands between 1999 and 2011, serogroup Y was most
frequently associated with meningococcemia, serogroup B with
meningitis, and serogroup C with combined meningococcemia
and meningitis [24].
Meningitis accounts for at least 50% of IMD cases worldwide
[11]. In the United States between 2001 and 2005, meningitis
was diagnosed in 70% of children aged 19 years with IMD [28].
Approximately, 20% of IMD is attributed to meningococcemia.
Symptoms include sudden fever, a nonblanching rash that may
worsen to purpura fulminans, hypotension, multiorgan failure,
and other manifestations of septicemia [5,11,17].
Meningococcal pneumonia occurs in 15% of patients but
may be underdiagnosed due to the inability to distinguish N
meningitidis in sputum samples as being invasive or carriage in
origin. Meningococcal pneumonia tends to occur in older adults
more often than younger adults; themedian age of these patients
in the United States has been reported at 68.5 years, compared
with 18 years for meningococcal meningitis or meningococcal
bacteremia [4]. Less frequently reported meningococcal di-
agnoses include epiglottitis, septic arthritis, urethritis, conjunc-
tivitis, and pericarditis [17].
Mortality
CFRs of 10%e20% persist among those who contract menin-
gococcal disease (Table 2) [4]. Globally, an estimated 135,000
deaths are attributed to IMD annually [2]. Risk factors for fatal
outcomes of all-cause bacterial meningitis include reduced
consciousness, tachycardia, and low cerebrospinal ﬂuid white
blood cell count [33]. IMD mortality is greatest in the elderly,
reaching as high as 20% in the United States [26]. In U.S. children
from 2001 to 2005, CFRs were 3.8% in those aged 5 years, 9.5%
in those aged 6e10 years, and 21.2% in those aged11 years [28].
In less developed countries, meningococcal meningitis incidence
is substantially higher, especially in the sub-Saharan “Meningitis
Belt.” In 2014, approximately 9.1% of IMD cases in Africa were
fatal although CFRs varied widely by country, reaching as high as
26.4% [29]. Fatality rates in Latin American countries range from
10% to 20% although higher CFRs have been associated with
speciﬁc serogroups during outbreaks [30].
Some studies have detected associations between serogroup
and mortality rate, with serogroups C and Y having higher CFRs
[26], whereas others have not found consistent associations
[24,28]. A Dutch study reported a CFR of 13% each for serogroup
Table 3
Sequelae associated with invasive meningococcal disease
Sequela Rate
Clinical diagnosis
Meningitis 8.2%e28% [24,26]
(unique study vs. review)
Meningococcemia 1.5%e33% [24,26]
Meningitis þ meningococcemia 3.5%e37% [24,26]
Serogroup
B 28%e41.3% [24,26,35]
C 22.2%e34% [24,35]
W 15% [24]
Y 54% [24]
Condition
Arthritis/vasculitis 4.7% [36]
Skin scarring 6.4%e48% [26,31,35]
Amputation/limb loss .8%e14% [26,31]
Seizures 1.4%e13.9% [31,37e39]
Cognitive impairmenta 2.9%e7.5% [26,40]
Hearing loss 2%e9.3% [26,31,37,39]
Visual abnormalitiesa 2.7%e13.7% [26,40]
Neuromotor disabilitya 1.2%e8.1% [26,40]
Neurologic impairments 13.5% (adult) [26],
2.4%e10.1% (pediatric) [26,35],
3.6% (all) [31]
Growth impairment 6%e13.1% [26]
Renal dysfunction 2%e8.7% [31,39]
a Includes values for all-cause bacterial meningitis.
Table 2
Case fatality ratios of invasive meningococcal disease by serogroup and age
group
Category Case fatality ratio
Global 5%e10% [12]
Overall
Industrialized region 7.3%e15.7% [15,26]
Undeveloped region 9.1%e26.4% [29,30]
Serogroup
A
C 9% [24]
W 13% [24]
Y 13% [24]
B 5.3%e12.5% [15,24,31]
Age group
<1 year 2% [24]
Serogroup B 8.1% [32]
Serogroup C/Y 4.9% [32]
1e<5 years 5%e7% [24]
Serogroup B 2.7% [32]
Serogroup C/Y 6.9% [32]
5e<10 years 4% [24]
Serogroup B 16.6% [32]
Serogroup C/Y 10.4% [32]
10e<19 years 4% [24]
20e<65 years 8% [24]
Serogroup B 9.5% [32]
Serogroup C/Y 13.9% [32]
65 years 39% [24]
Serogroup B 41.3% [32]
Serogroup C/Y 21.3% [32]
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the overall CFR for serogroupWwas highest (16.3%), followed by
serogroups C (14.7%), Y (12.0%), and B (10.6%) [4,34]. CFRs may
also vary by clinical presentation of IMD, with septic shock and
combined meningitis/septic shock causing more deaths than
meningitis alone [24].Morbidity
Long-term consequences of meningococcal infection may be
severe. Up to 20% of survivors experience permanent signiﬁcant
sequelae, with these proportions varying by age and the severity
of infection [8,24]. Although associations between severity of
sequelae and serogroups have been inconsistent [24], one study
from Great Britain reported more severe sequelae associated
with serogroup C disease than serogroup B [26].
Sequelae may be physical, neurologic, cognitive, and psychi-
atric (Table 3). Skin necrosis, seizures, deafness, ataxia, and
amputation represent several types of sequelae reported among
IMD survivors [28]. Overall, the most frequently reported long-
term sequelae are hearing loss, cognitive defects, and visual ab-
normalities [26].
Amongphysical sequelae, skin scarringoccursmost frequently
and is associated with meningococcemia [26]. Amputation, also
associated with meningococcemia, occurs less frequently and
may range from loss of a digit to loss of single or multiple limbs.
Amputation rates range from .8% to 14% depending on study
sample size [26]. In addition, bone growth plates may be sufﬁ-
ciently damaged during acute IMD infection to cause differences
in limb length or arrest of growth altogether [26].
Neurologic effects of IMD include deﬁcits in memory and
executive function, unilateral or bilateral hearing loss, seizures,and chronic pain. Hearing loss has been reported in approxi-
mately 2%e6% of survivors [26,37]. Epilepsy has been recorded in
2% of children diagnosed with serogroup B IMD [37], and the
global rate of unprovoked seizures in meningococcal meningitis
survivors is estimated at 1.4% [38]. Children diagnosed with all-
cause bacterial meningitis as infants were estimated to have a
substantially higher risk for severe or moderate disabilities at
5 years of age compared with controls, but these risks varied
depending on infecting organism [40]. Survivors of IMD may
experience mild to severe cognitive sequelae, including difﬁculty
concentrating, low academic achievement, and deﬁcits in exec-
utive function that have consequences into adulthood for
educational achievement [26,41]. Signiﬁcant differences were
reported in cognitive and behavioral assessments between IMD
survivors and control groups [26]. In a large Danish study, 11%
fewermeningococcal meningitis patients completed high school,
and 7.9% fewer patients achieved higher education [42].
Psychiatric effects of meningococcal disease may be short-
lived or may manifest as long-term consequences, especially
for pediatric patients and their parents. Two studies documented
an increased risk for post-traumatic stress disorder (PTSD) in
children diagnosed with meningococcal disease, and parents or
caregivers may also experience long-term effects from the stress
associated with an acute and potentially fatal illness in a child
[26,43]. Most of the studies assessing the burden of IMD focus on
the acute phase or soon after hospitalization, meaning the mid-
to long-term psychiatric impact of IMD are probably under-
recognized.
Reduction in the quality of life (QoL) in IMD patients is
dependent on the type and severity of sequelae. One study re-
ported a reduction in QoL in 23% of IMD survivors who
completed a survey designed to assess emotional and physical
health [44]. In a second study, survivors with intellectual and
behavioral deﬁcits scored worst, suggesting that cognitive
impairment may be an equally important contributor to loss of
Table 4
Direct and indirect costs associated with invasive meningococcal disease
Clinical presentation Cost (USD for study year also shown)
Direct Indirect
Pediatric cost (range; USD) Adult cost (range) Overall cost (SD) Pediatric cost (range) Adult cost (range) Overall
Meningococcal disease
Developed countries V6,800 [25]a [$8,976]
£157,101e£136,401 [45]
($247,434e$214,831)b
V8,250 [25]a [$10,890] $65,980 [46]c
$46,736 ($109,924.40) [39]c
Undeveloped countries $175 ($62e$1,442) [47]d,e
$1,289 ($207e$7,076) [48]b,e
$162 ($115e$248) [49]f,e
$90e$244 [50]g $46 ($0e$863) [47]d,e
By clinical presentation
Meningococcemia $79,648 [46]c
Meningitis $56,202 [46]c
Other $69,269 [46]c
Outbreak containment Large-scale cost (range) Small-scale cost (range) Large-scale cost (range) Small-scale cost (range)
Developed countries $55,755 ($26,371e$91,046) [51]b $41,857
($14,085e$69,629) [51]b
$579,851 ($105,484e$1,081,627) [51]b $299,641
($42,254e$557,028) [51]b
Undeveloped countries $2,222 ($.31e$6,465) [51]b $3,407,590 ($58,363e$9,726,937) [51]b
Sequelae With (annual) Without (annual)
Annual V4,147.69 [25]a ($5,474.95) V489 [25]a ($646)
Lifelong V1,183,272eV3,149,676 [52]h
($1,514,588e$4,031,585)
SD ¼ standard deviation; USD ¼ United States dollar.
a Cost reported in 2013 euro.
b Cost reported in 2010 USD.
c Cost reported in 2009 USD.
d Cost reported in 2012 USD.
e Includes values for all-cause bacterial meningitis.
f Cost reported in 2005 USD.
g Cost reported in 2006 USD.
h Cost reported in 2012 Euro.
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estimated effects of IMD sequelae in terms of quality-adjusted
life-years lost differed by type and severity of sequela. If 1.0
represents 1 year in perfect health, quality-adjusted life-years
lost for sequelae from most to least severe were calculated to be
.94 for severe neurologic disability, .74 for blindness, .46 for
cognitive deﬁcits, .39 for amputation with substantial disability,
and .19 for hearing loss [25].
Economic Burden of Disease
Costs associated with meningococcal disease vary by clinical
presentation and geographic region and may be categorized as
direct, indirect, and societal (Table 4). Direct costs are associated
with treatment of the acute phase of IMD, usually described in
terms of hospitalization costs. Indirect costs encompass follow-
up treatment and expenses associated with disease sequelae.
Societal costs may be measured in terms of loss of QoL as a result
of meningococcal infection.
Direct costs
The economic burden of IMD depends on the economic status
of the country and whether health care is government-
sponsored or private. Treatment costs frequently comprise a
greater proportion of the per capita gross domestic product in
low-income countries. Costs to rural households in low-income
countries are generally lower than for urban households but
may comprise a greater proportion of household income [50].
Between 1990 and 2010, average costs per IMD case duringoutbreaks in high-income and low-income countries were esti-
mated at $41,857 to $55,755 and $2,222 (USD), respectively [51].
Developed countries. The total one-year direct cost burden of
IMD in U.S. hospitals has been estimated at $76 million (USD),
which corresponds to $65,980 per case. Costs vary by clinical
diagnosis; treatment for septicemia costs approximately 40%
more than treatment for meningitis ($79,648 vs. $56,202 per
case) [46]. In Europe, pediatric hospitalization costs in Italy have
been estimated at V6,800 ($8,976 for same study year) per stay,
and atV8,250 ($10,890) for adult hospitalizations [25]. A study of
two IMD cases in Spain estimated costs in the year of acute illness
to range from V121,896 ($156,027) to V168,251 ($215,361),
depending on clinical diagnosis [52]. In the United Kingdom,
acute costs per case for septicemia and meningitis treatment,
respectively, were estimated at £157,101 ($247,434) and £136,401
($214,831) [45].
Undeveloped countries. The average cost per household per IMD
case in sub-Saharan Africa was estimated at $90 without
sequelae and $244 if sequelae were present [50]. One study of
pediatric all-cause bacterial meningitis in Senegal estimated a
mean cost per acute episode of $1,289 (range, $207e$7,076) [48].
A study of economic health care burden in Kenya reported a
median cost for pediatric all-cause bacterial meningitis of $162
(range, $115.16e$248.14) [49]. In Vietnam, the median direct cost
associated with all-cause bacterial meningitis treatment in
children aged <5 years was estimated at $175 (range,
$62e$1,442), which included medication, medical supplies, di-
agnostics, bed-days, and outpatient costs [47]. The limitation of
F. Martinón-Torres / Journal of Adolescent Health 59 (2016) S12eS20S16studies reporting all-cause bacterial meningitis is the lack of
speciﬁcity for meningococcal meningitis.
Indirect costs
Beyond the expenses associated with diagnosis and hospi-
talization, ﬁnancial input is necessary to address sequelae in IMD
survivors. Costs are highly dependent on severity of the sequelae
and can vary between and within countries.
Developed countries. Costs associated with caring for those who
have survived meningococcal disease can be overwhelming.
Although IMD is relatively rare compared with other infectious
diseases, approximately 20% of survivors require continued
treatment for sequelae after the primary infection is resolved,
placing a substantial burden on health services and families.
Excluding initial hospitalization, approximately $37 million are
spent for follow-up care in the ﬁrst year after diagnosis [46].
Among patients enrolled in a managed care program in the
United States between 1998 and 2009, those reporting sequelae
incurred substantially higher costs for ofﬁce visits, home health
care costs and medical equipment, and pharmacy costs [39]. A
Spanish study reported lifelong costs for treatment of an IMD
patient diagnosed with severe sequelae, including neurologic
deﬁcits, at V1.18 million to V3.14 million ($1.51 million to $4.01
million), including V121,896 to V168,251 ($156,026 to $215,361)
for medical costs in the ﬁrst year after diagnosis and an average
of V32,509 ($41,612) per year for the rest of the patient’s life for
social care costs. An Italian study reported the average annual
cost per person with sequelae as approximately V4,100 ($5,412),
whereas survivors without sequelae were estimated to pay
nearly 10-fold less (V489 [$646]) in follow-up costs in the ﬁrst
year after IMD diagnosis [25].
Undeveloped countries. The enormous costs associated with
surviving meningococcal disease are even more overwhelming
for those living in low-income countries. Although actual dollar
ﬁgures may be relatively low compared with indirect costs re-
ported in high-income countries, the resources required to pro-
vide for a survivor may comprise a disproportionately large
portion of household annual income. Indirect costs associated
with hospitalization for pediatric all-cause bacterial meningitis
in Vietnam were estimated at $46 [47]. Over the course of a
lifetime, these expenses may ﬂuctuate, depending on need for
rehospitalization or for long-term care of a patient with severe
sequelae. Total costs for a 30-year lifetime of care for Senegalese
pediatric all-cause bacterial meningitis survivors were estimated
at $36,336 (range, $477e$99,528) [48].
Societal costs
Costs associated with a lifetime of care for survivors of IMD
place substantial burdens on government health care resources
or health insurance providers. Not unexpectedly, survivors with
sequelae require greater investment of societal resources, and
those with severe sequelae require the greatest input [52].
A Vietnamese study estimated the mean (standard deviation)
cost for treating all-cause bacterial meningitis from a societal
perspective at $727 ($865), which is approximately fourfold
higher than the cost of care during the acute phase of disease
[47]. A Spanish study of two cases of IMD estimated that social
care costs within one year of diagnosis ranged from V28,665 toV33,330 ($36,691 to $42,662) and cost approximately V27,000
($34,560) per year for the rest of the patient’s life [52]. Lifelong
rehabilitation costs from a government perspective in the United
Kingdom were estimated to range from £1.368 to £3.038 million
($2.155 to $4.785 million) for meningococcal septicemia and
from £1.721 to £4.474 million ($2.711 to $7.047 million) for
meningococcal meningitis [45].
Outbreaks of meningococcal disease in particular are asso-
ciated with high societal costs encompassing IMD treatment,
containment strategies, and community disruption or anxiety.
Costs associated with reactions to outbreaks are largely borne
by public health departments, which are given the difﬁcult task
of budgeting ﬁnancial and human resources to address out-
breaks. These departments must coordinate targeted vaccina-
tion in the outbreak population and prophylactic antibiotic
administration in close contacts of the disease case. In high-
income countries for the period 1990 to 2010, outbreak man-
agement costs such as those above were estimated at $299,641
per small containment strategy and $579,851 per large
containment strategy. Management costs for low-income
countries for the same period were estimated at $3,407,590
per large containment strategy [51]. A study of costs associated
with the management of a cluster of IMD in England reported
that managing two cases of meningococcal infection cost
nearly 17 times more than the management of a single case
(£317 vs. £5,584 [$502 vs. $8,845]). The largest component of
this difference in cost was attributed to additional health
department staff time required to manage the outbreak rather
than costs associated with prophylactic antibiotics or medical
equipment [53].
Neglected Burden of Disease
The burden of meningococcal disease is most often measured
quantitatively in terms of fatality rates and cost of treatment,
which leaves other more qualitative categories of disease burden
underrepresented. In addition, most of the available data on the
burden of disease refer to the acute phase of disease. Because
little data are available describing these neglected aspects, these
components may not be sufﬁciently emphasized in the collection
of data that policymakers consider when evaluating vaccination
programs aimed toward proactively preventing rather than
managing meningococcal disease. Prevention of IMD through
vaccination obviates these less visible, but nonetheless impor-
tant, burdens of disease (Table 5).
Long-term cognitive and psychiatric burden
Cognitive, psychosocial, and psychiatric sequelae are usually
only considered in the short term and are systematically
neglected as long-term sequelae when considering the effects of
IMD. Very few studies have aimed to assess this particular
burden in depth and even fewer with a long-term perspective.
Only through additional long-term follow-up studies will these
less obvious defects be detected and described rigorously.
Consequences of treatments administered during hospitali-
zation for meningococcal disease are not often considered in
descriptions of IMD burden. Sedatives and analgesics are
frequently given to IMD patients and may exert negative in-
ﬂuences on neuropsychological health. A Dutch study evaluating
IMD patients four or more years after hospital discharge reported
an association between the use of morphine, fentanyl, and
Table 5
Neglected burden of invasive meningococcal disease and all-cause bacterial
meningitis
Burden Description
Cognitive impairment Learning disabilities, behavioral deﬁcits, lower
educational achievement [25,26,41,42,54,55]
Psychological stress Post-traumatic stress disorderelike symptoms (in
patients and caregivers); depressive symptoms
[23,26,43,56e59]
Family burden Loss of income often required to allow a caregiver to
devote sufﬁcient time to the survivor; siblings
also may be negatively affected; emotional stress
in caregivers [47,48]
Adaptive measures Rehabilitation costs, special education plans,
medical devices (hearing devices, prostheses)
[26,48]
Legal burden Cost of retaining lawyers for malpractice suits; lost
productivity associated with legal complaints;
damages awarded to plaintiff [60e62]
Fear of meningococcal
disease
Increased clinical work and testing (bloodwork,
cerebrospinal ﬂuid sampling), unnecessary
treatments or hospitalizations ordered by
treating physicians to rule out meningococcal
disease
Social crisis
management
Logistical planning associated with managing
outbreaks (vaccine purchase, storage,
administration, and follow-up surveillance) [63]
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visual, and executive function [54].
Several reports have noted signiﬁcant negative psychological
effects among children surviving IMD, including emotional and
behavioral issues. As many as 62% of children treated for IMD
experienced symptoms consistent with post-traumatic stress,
and approximately 10% of children met diagnostic criteria for
PTSD [26]. Among children hospitalized with meningococcal
septic shock, adolescents aged 12e17 years reported lower
global self-worth than age-matched controls, particularly
among patients with skin scarring [56]. How these experiences
in childhood may inﬂuence adult psychological well-being is
unknown.
Signiﬁcant cognitive deﬁcits relating to number and word
ﬂuency have also been detected among IMD survivors evaluated
4e16 years after hospitalization [55]. One of the few studies to
report data related to educational achievement in adults after
pediatric all-cause bacterial meningitis concluded that economic
self-sufﬁciency is compromised in meningitis survivors, with a
substantial component of the deﬁciency stemming from strain
placed on the family [42].Family burden
Coping with an IMD diagnosis imparts a substantial
emotional and psychological burden on family members or
caregivers, especially when potentially faced with a new reality
of economic sacriﬁce and loss of QoL. Studies of the effects on
QoL after diagnosis with meningococcal disease speciﬁcally
(as opposed to pneumococcal or general bacterial meningitis)
are somewhat rare. The burden of IMD on a family may be
described in economic terms such as loss of income to care for a
survivor but should also include the less easily quantiﬁable
facets of the emotional burden experienced by parents who
must care for a child with physical, psychological, or cognitive
disabilities.In a study of all-cause pediatric meningitis in Vietnam,
approximately half of caregivers lost income because of the
child’s illness, and nearly one third were forced to use additional
sources of payment, such as borrowing and sale of household
assets, to cover medical costs. In addition, paid work days lost
due to caring for the ill child were estimated at 16.6 days. Overall,
the economic burden of caring for a child with all-cause bacterial
meningitis represented approximately 83% of the household’s
monthly income [47]. Sequelae that are severe enough, and last
long enough, to prevent a child in a low-income country from
attending school may place an additional burden on family
members to provide childcare while the primary household
earners are at work. Among pediatric all-cause bacterial men-
ingitis survivors in Senegal who did not attend school, 61% were
kept home because of meningitis sequelae, and 81% of house-
holds reported an adult foregoing work to care for the child [48].
Hospitalization for IMD may elicit negative psychological ef-
fects in both patients and caregivers (i.e., children and their
parents) [57]. Parents of critically ill children are placed under
enormous stress; short-term studies of emotional health in
mothers of children with IMD indicated a substantial increased
risk for developing PTSD [26]. Problems of emotion, hyperactiv-
ity, and behavior were observed at a three-month follow-up time
point among 60 IMD survivors aged 3e6 years. Approximately,
43% of the parents of those children were considered at risk for
psychiatric disorders, and 19%e38% were considered at risk for
PTSD [58]. In a study of 86 parents of children diagnosed with
IMD in the United Kingdom, 23% of mothers and 11% of fathers
were considered at risk for PTSD 12 months after their child was
hospitalized [59].
The long-term psychological effects of IMD on caregivers are
not well characterized. In a survey of 164 parents of children
hospitalized with meningococcal septic shock, most parents
recovered from the initial psychological distress associated with
caring for a child hospitalized for a potentially fatal illness, but
after 4 years or more, nearly one quarter of parents were
considered at risk for psychiatric disorders [23].
Adaptive measures
Consequences of IMD with sequelae may require extensive
follow-up treatment and adaptive measures necessary to rein-
troduce an IMD survivor into society. As hearing loss, motor
deﬁcits, and cognitive deﬁcits are among the most frequently
reported sequelae, hearing devices, physiotherapy, and special-
ized education are necessary to restore a survivor to a QoL as
close to normal as possible. Although limb amputation is not as
common as other types of sequelae, costs associated with pros-
thetics may be much higher than costs for other adaptive mea-
sures. In high-income countries, costs associated with these
services are frequently covered by government-sponsored health
care, but in low-income countries, these types of adaptive mea-
sures are often out of the ﬁnancial reach of the average house-
hold. In Senegal, for example, approximately 83% of caregivers of
children with all-cause bacterial meningitis were aware of
treatments or adaptive measures that would beneﬁt their child
but did not access the treatment due to an inability to cover the
cost [48].
Sequelae sometimes may not be linked to a past episode of
IMD because of a substantial length of time between hospitali-
zation and manifestation of the effects of the disease, thus
requiring intervention at a much later time. For example, effects
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clinical effect many years later as asymmetric or arrested limb
growth [26], rendering a link between the effect and the infec-
tion difﬁcult to discern and therefore difﬁcult to report as part of
the burden of IMD.
Legal burden
Clinical presentation of meningococcal disease may vary in
onset and severity and often mimic symptoms of less severe
infections. These characteristics may consequently render a
timely and accurate diagnosis difﬁcult. Patients who are not
diagnosed correctly may turn to legal action with claims of
medical malpractice (noniatrogenic/misdiagnosis) to secure
compensation for lost QoL. The ﬁnancial outlay and lost pro-
ductivity associated with legal complaints place a substantial
ﬁnancial burden on both plaintiff and defendant, whether the
defendant is a privately practicing physician, a health care
network, or a government-run public health ministry. Out-of-
court settlements and damages awarded to plaintiffs are also
components of the legal burden associated with meningitis, for
example (all-cause bacterial meningitis in this case) [60]. In a
study of malpractice cases brought due to all-cause meningitis
contracted after otolaryngologic procedures, untimely diagnosis
and permanent deﬁcits were the two most frequently reported
allegations [61]. As a practical example, the United Kingdom’s
Joint Committee on Vaccination and Immunization has recently
agreed that these legal costs and compensation for factors other
than QoL losses may represent additional costs to governmental
health services and should be taken into account in the cost-
effectiveness analysis when assessing the use of meningococcal
B vaccine as part of the national immunization program [62].
Fear of meningococcal disease
One of the most important challenges for a practitioner in the
ﬁrst line of health care (i.e., in a primary care or emergency room
setting), is the possibility of missing a case of IMD in the initial
stages of the disease, when IMD is clinically indistinguishable
from any other general syndrome of an infectious disease. This
“fear of meningococcal disease” is partially related to the legal
burden associated with IMD regarding misdiagnosis by the
treating physician or the “the risk of doing nothing.” In an effort
to provide the most comprehensive care for a patient and rule
out IMD as a diagnosis, physicians may invest speciﬁc work time,
order additional bloodwork, cerebrospinal ﬂuid sampling, or
other potentially invasive tests. After the diagnostic workup,
doubtful or inconclusive cases may be hospitalized for initial
observation or empirical therapy while awaiting the clinical
course. In many of these cases, these procedures and measures
are later shown to have been unnecessary on a ﬁnal diagnosis
after ruling out IMD. To our knowledge, no report in the literature
has attempted to speciﬁcally measure this burden.
Social crisis management costs
Meningococcal disease outbreaks constitute a major public
health burden owing not only to their unpredictability but also to
the expenses associated with treating close contacts of an
infected person and implementing strategies to contain the
outbreak [63]. Outbreaks may be brief or last several years; the
public health resources required to manage an outbreak includeexpenses for prophylactic antibiotics and less tangible costs
associated with vaccination campaigns, educational campaigns,
and surveillance. Outbreaks at U.S. universities have placed se-
vere ﬁnancial burdens on the universities, which were required
to quickly coordinate vaccine purchase, storage and handling,
and campus-wide advertisement campaigns to support vacci-
nation clinics aimed at preventing disease spread [64].
Discussion
Considering the facets of meningococcal disease burden
outlined previously, particularly those that are underreported or
overlooked, the optimal strategy to reduce overall IMD burden is
prevention through vaccination. Vaccines protecting against IMD
caused by serogroups A, C, W, Y, and more recently, B, are now
available, and public health authorities must evaluate such
vaccines from different perspectives before recommending them
in national immunization programs. A recent example of a
successful meningococcal vaccination strategy is the phased
introduction of the serogroup A conjugate vaccine PsA-TT
(Meningococcal A conjugate vaccine), which was implemented
in Africa starting in 2010 to control cyclical serogroup A IMD
outbreaks [65]. Among countries participating in surveillance,
the incidence of serogroup A meningitis decreased by more than
10-fold [65]. The vaccination program also nearly eliminated
serogroup A carriage in thosewhowere andwere not vaccinated,
providing evidence for a herd effect and further protection from
disease [66]. Signiﬁcant effects on disease incidence and carriage
combined to make this vaccine extremely effective.
Vaccines may be costly to produce; thus, the economic in-
vestment they require may present a barrierdif not the main
barrierdto recommendation [67]. Few studies have examined
the nonclinical/economic burdens of meningococcal disease,
which greatly affect the body of data considered during cost-
effectiveness evaluations.
Immunization with a MnB vaccine would optimize IMD con-
trol [68]. Current MnB clinical disease burden is likely under-
estimated in countries where molecular diagnostics are not
routinely used due to limitations in the detection ofNmeningitidis
caused by interference of early antibiotic treatment with micro-
biological culture detectionmethods [69]. In addition to this likely
underestimation of disease burden, vaccine efﬁcacymodeling has
focused on direct protection to estimate cost-effectiveness and
numbers needed to vaccinate. The types of static models used are
susceptible to inaccurate estimation due to the comparatively
lower incidence of IMD than other vaccine-preventable infectious
diseases [69]. The severity of sequelae, long-term outcomes, and
litigation costs that could be reduced by prophylactic vaccination
should be important aspects of the burden of meningococcal
disease considered during economic evaluation [26,69].
A MnB vaccine (4CMenB) was recently approved for inclusion
in the national immunization program in the United Kingdom
only after multiple iterations of cost-effectiveness modeling and
price negotiations with the vaccine manufacturer [70]. In March
2014, the UK’s Joint Committee on Vaccination and Immuniza-
tion issued a statement supporting the introduction of the
4CMenB vaccine to the routine infant immunization program but
only at a cost-effective price per dose [71]. Initial cost-
effectiveness estimates indicated that vaccination would not be
cost-effective at any price, but after adjusting inputs into the
original model, the outcome favored recommendation. This
example highlights the need for careful review of the often
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tions for vaccines, particularly for new vaccines without a history
of widespread use, and for vaccines targeting rarer infectious
diseases for which changes in incidence may be difﬁcult to track.
Methodology intended to evaluate the cost-effectiveness of
curative treatments places preventive treatments such as vac-
cines at a disadvantage [67].
Summary and Future Considerations
The global clinical burden of IMD is substantial, persistent,
and unpredictable. Surviving patients may experience sequelae
ranging from skin scarring to hearing impairment to limb
amputation, which undoubtedly reduce the patient’s QoL. Major
economic burdens are also incurred during hospitalization and
after discharge. On a larger scale, management of meningococcal
disease outbreaks in communities or university campuses re-
quires extensive ﬁnancial outlays by public health resources. In
addition, considering that most cases occur in otherwise healthy
subjects, the most effective strategy to reduce the total burden of
meningococcal disease is prevention through vaccination.
Less easily quantiﬁable outcomes and costs associated with
meningococcal disease (Table 5) are consistently neglected when
calculating disease burden. Consequently, these factors are not
usually included in cost-effectiveness analyses when proposed
vaccination programs are evaluated by public health authorities
for inclusion in national immunization programs. To improve the
accuracy of cost-effectiveness analyses for meningococcal vac-
cines, or any new vaccine, themedical communitymust advocate
for a change in the methods by which these vaccines are evalu-
ated from the health economic perspective, andmust ensure that
all disease burden is measured and accounted comprehensively.
No modern health system can afford to use a speculative
economic model that inhibits introduction of a potentially
effective disease-prevention strategy. Health economics should
serve as guides for, rather than determinants of, immunization
policy [67]. No matter how meningococcal disease burden is
interpreted, IMD is now a vaccine-preventable disease.
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